1. De Waal et al. J. Immunol. 150: 4754-4765, 1993.* |
1. Martin-Foutecha et al. Eur. J. Immunol. 26: 1851-1859 (1996).* |
2. Leong et al. Int. J. Cancer 71: 476-482 (1997).* |
1. Baskar et al. PNAS 90: 5687-5690 (1980).* |
2. Townsend et al. Science 259: 368-370 (1993).* |
3. Chen et al. Cell 71: 1093-1102 (1992).* |
4. Chen et al. Immunol. Today 14: 483-486 (1993).* |
5. Gilboa Sem. On Cology 23: 101-107 (1996).* |
6. Dermer Biotechnology 12: 320 (1994).* |
7. Osband Immunol. Today 11: 193-195 (1990).* |
8. Boon Int. J. Cancer 54: 177-180 (1993).* |
9. Boon Adv. Cancer Res. 58: 177-210 (1992).* |
Azuma, M., et al., “B70 Antigen is a Second Ligand for CTLA-4 and CD28,” Nature, vol. 366, 76-79 (1993). |
Bell, G. and Imboden, J., “CD2 and the Regulation of T Cell Anergy,” The Journal of Immunology, 2805-2807 (1995). |
Beverly, B., et al., “Reversal of in Vitro T Cell Clonal Anergy by IL-2 Stimulation,” International Immunology, vol. 4, No. 6, 661-671 (1992). |
Bierer, B., et al., “Interaction of CD2 with its Ligand, LFA-3, in Human T Cell Proliferation,” The Journal of Immunology, vol. 140, No. 10, 3358-3363 (1988). |
Bierer, B., et al., “Synergistic T Cell Activation Via the Physiological Ligands for CD2 and the T Cell Receptor,” J. Exp. Med., vol. 168, 1145-1156 (1988). |
Boussiotis, V., et al., “B7 but not Intercellular Adhesion Molecule-1 Costimulation Prevents the Induction of Human Alloantigen-specific Tolerance,” J. Exp. Med., vol. 178, 1753-1763 (1993). |
Boussiotis, V., et al., “CD2 is Involved in Maintenance and Reversal of Human Alloantigen-specific Clonal Anergy,” J. Exp. Med., vol. 180, 1665-1673 (1994). |
Boussiotis, V., et al., “Human Alloantigen Specific Clonal Anergy to Lymphoblastoid Cells is Reversed Following Culture with IL-2 or IL-4,” Blood, vol. 82, 304A (1993). |
Brottier, P., et al., “T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation Via CD2-D66 Plus CD2-9.6/T111 Epitopes,” The Journal of Immunology, vol. 135, No. 3, 1624-1631 (1985). |
Dustin, M., et al., “Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface,” Nature, vol. 329, 846-848 (1987). |
Freedman, A., et al., “B7, a B Cell-Restricted Antigen that Identifies Preactivated B Cells,” Division of Tumor Immunology, Dana-Farber Cancer Institute and the Department of Medicine. The Journal of Immunology 3260-3267 (1987). |
Freeman, G., et al., “B7, a new Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells,” The Journal of Immunology, vol. 143, No. 8, 2714-2722 (1989). |
Freeman, G., et al., “Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation.” Science, vol. 262, 909-911 (1993). |
Freeman, G., et al., “Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production.” The Journal of Experimental Medicine, vol. 178, 2185-2192 (1993). |
Freeman, G., et al., “Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7,” J. Exp. Med., vol. 174, 625-631 (1991). |
Freeman, G., et al., “Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice,” Science, vol. 262, 907-909 (1993). |
Gimmi, C., et al., “B-cell Surface Antigen B7 Provides a Costimulatory Signal that Induces T Cells to Proliferate and Secrete Interleukin 2,” Proc. Natl. Acad. Sci. USA, vol. 88, 6575-6579 (1991). |
Gimmi, C., et al., “Human T-cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation,” Proc. Natl. Acad. Sci. USA, vol. 90, 6586-6590 (1993). |
Harding, F., et al., “CD28-mediated Signaling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones,” Nature, vol. 356, 607-609 (1992). |
Hathcock, K., et al., “Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation,” Science, vol. 262, 905-907 (1993). |
Koyasu, S., et al., “Role of Interaction of CD2 Molecules with Lymphocyte Function-associated Antigen 3 in T-cell Recognition of Nominal Antigen,” Proc. Natl. Acad. Sci. USA, vol. 87, 2603-2607 (1990). |
Lenschow, D., et al., “Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig,” Science, vol. 257, 789-791 (1992). |
Lin, H., et al., “Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion,” J. Exp. Med., vol. 178, 1801-1806 (1993). |
Linsley, P., et al., “Binding of the B Cell Activitation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med., vol. 173, 721-730 (1991). |
Linsley, P., et al., “Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule,” Science, vol. 257, 792-795 (1992). |
Meuer, S., et al., “An Alternative Pathway of T-Cell Activation: A Functional Role for the 50 kd T11 Sheep Erythrocyte Receptor Protein,” Cell, vol. 36, 897-906 (1984). |
Moingeon, P., et al., “CD2-mediated Adhesion Facilitates T Lymphocyte Antigen Recognition Function,” Nature, vol. 339, 312-314 (1989). |
Pepinsky, R., et al., “The Increased Potency of Cross-linked Lymphocyte Function-associated Antigen-3 (LFA-3) Multimers is a Direct Consequence of Changes in Valency,” The Journal of Biological Chemistry, vol. 266, No. 27, 18244-18249 (1991). |
Seed, B., “An LFA-3 cDNA Encodes a Phospholipid-linked Membrane Protein Homologous to its Receptor CD2,” Nature, vol. 329, 840-842 (1987). |
Selvaraj, P., et al., “The T Lymphocyte Glycoprotein CD2 Binds the Cell Surface Ligand LFA-3,” Nature, vol. 326, 400-403 (1987). |
Tan, P., et al., “Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with its Natural Ligand B7/BB1,” J. Exp. Med., vol. 177, 165-173 (1993). |
Van Gool, S., et al., “The Combination of Anti-B7 Monoclonal Antibody and Cyclosporin A Induces Alloantigen-specific Anergy During a Primary Mixed Lymphocyte Reaction,” J. Exp. Med., vol. 179, 715-720 (1994). |
Wallner, B., et al., “Primary Structure of Lymphocyte Function-Associated Antigen 3 (LFA-3) The Ligand of the T Lymphocyte CD2 Glycoprotein,” Journal of Experimental Medicine, vol. 166, 923-932 (1987). |
Yang, S., et al., “A Common Pathway for T Lymphocyte Activation Involving Both the CD3-Ti Complex and CD2 Sheep Erythrocyte Receptor Determinants,” The Journal of Immunology, vol. 137, No. 4, 1097-1100 (1986). |